# US 2023/0148151 A1 · Process for the synthesis of a conjugate of hyaluronic acid and paclitaxel

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0148151 A1
- Document ID: US20230148151A1
- Status: Published application
- Kind: A1
- Application number: 17/917,653
- Filed: 2021-04-15
- Published: 2023-05-11
- Earliest claimed: 2020-04-17
- Assignees: Fidia Farmaceutici S.P.A.
- Applicants: FIDIA FARMACEUTICI S.p.A.
- Inventors: Monica CAMPISI; Cristian GUARISE; Carlo PIZZOCARO
- Web page: https://patentgrep.com/patent/US20230148151A1

## CPC

- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61K 31/337: having four-membered rings, e.g. taxol
- A61P 35/00: Antineoplastic agents
- C08B 37/0072: {Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates}
- C08L 5/08: Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)

## Abstract

An industrial synthesis process of a hyaluronic acid-paclitaxel conjugate obtained by introducing the 4-bromobutyric acid spacer/linker between the hyaluronic acid and the paclitaxel, said conjugate being characterized by a high purity, the related pharmaceutical compositions for use in the treatment of multiple cancer forms are described.

## Claims

### Claim 1

A process for the prepaation and purification of a hyaluronic acid-paclitaxel (HA-paclitaxel) conjugate which comprises or consists of the following steps:
a) activating in a solution of paclitaxel in an organic solvent, containing a 4-bromobutyric acid spacer/linker, of the carboxyl group of the 4-bromobutyric acid spacer/linker with an activating agent in the presence of a catalyst, thereby obtaining an intermediate of the HA-paclitaxel conjugate;
b) crystallizing of the intermediate obtained from the previous step a), in an organic solvent, subsequently filtering and drying;
c) adding the crystallized intermediate obtained in the previous step b) to a TBA (tetrabutylammonium) salt of HA in DMSO;
d) purifying the HA-paclitaxel conjugate thus obtained which has an ester bond between the carboxyl of the HA polysaccharide and the spacer/linker, said spacer/linker being in turn bound by an ester bond through its carboxyl to the hydroxyl group at carbon C2′ of paclitaxel, by precipitation with an ethanol/water solution containing the NaBr salt, subsequently washing at least once in ethanol/water and further washing in ethanol, pre-drying at 40° C. and passage in a saturated chamber of water vapour at 40° C. and at atmospheric pressure, finally drying at 40° C. under vacuum.

### Claim 2 (depends on 1)

The process according to claim 1, wherein in the activation step a), the activating agent is a carbodiimide.

### Claim 3 (depends on 1)

The process according to claim 1, wherein in the activation step a), the catalyst is 4-dimethylaminopyridine (DMAP).

### Claim 4 (depends on 1)

The process according to claim 1, wherein in the crystallization step b), the solvent is N-heptane.

### Claim 5 (depends on 1)

The process according to claim 1, wherein in the purification step d), the pre-drying and the passage in a saturated chamber of water vapour at atmospheric pressure are carried out at 40° C., for a time of at least 8 hours, whereas the drying step is carried out at 40° C., under vacuum, for a time of at least 16 hours.

### Claim 6 (depends on 1)

The process according to claim 1, wherein the starting hyaluronic acid has an average weight molecular weight ranging from 400 to 3×106 Da.

### Claim 7 (depends on 1)

The process according to claim 1, wherein the starting hyaluronic acid is of an extractive origin from rooster combs, biotechnological or fermentative origin.

### Claim 8 (depends on 1)

The process according to claim 1, wherein the starting hyaluronic acid is of a fermentative origin with an average weight molecular weight ranging from 140,000 to 250,000 Da.

### Claim 9

A HA-paclitaxel conjugate having a derivatization or esterification degree within the range of 15% to 21% w/w, preferably within the range of 16% to 20% w/w, wherein the starting hyaluronic acid is of a fermentative origin with an average weight molecular weight ranging from 140,000 to 250,000 Da, said conjugate being in the form of a fine and homogeneous powder, with a degree of purity greater than 98% by weight on the dry product and containing a quantity of di-Br-paclitaxel of less than 1% by weight.

### Claim 10 (depends on 1)

A HA-paclitaxel conjugate in the form of a fine and homogeneous powder containing a quantity of di-Br-paclitaxel of less than 1% by weight, prepared and purified according to the process of claim 1.

### Claim 11 (depends on 10)

The conjugate according to claim 10, wherein the derivatization or esterification degree is within the range of 15% to 21% w/w.

### Claim 12 (depends on 9)

A method of treating cancer, which comprises administering to a patient in need thereof a pharmaceutical composition essentially consisting of the conjugate according to claim 9, associated with pharmacologically acceptable diluents/excipients, wherein the cancer is advanced breast cancer, lung cancer, ovarian cancer, bladder cancer, prostate and endometrial cancer and/or mesothelioma.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the composition is formulated in sterile, isotonic water, containing 5% w/v of glucose.

### Claim 14 (depends on 2)

The process according to claim 2, wherein the activating agent is 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC).

### Claim 15 (depends on 11)

The process according to claim 11, wherein the derivatization or esterification degree is within the range of 16% to 20% w/w.

### Claim 16 (depends on 3)

The process according to claim 3, wherein in the crystallization step b), the solvent is N-heptane.

### Claim 17 (depends on 2)

The process according to claim 2, wherein in the purification step d), the pre-drying and the passage in a saturated chamber of water vapour at atmospheric pressure are carried out at 40° C., for a time of at least 8 hours, whereas the drying step is carried out at 40° C., under vacuum, for a time of at least 16 hours.

### Claim 18 (depends on 3)

The process according to claim 3, wherein in the purification step d), the pre-drying and the passage in a saturated chamber of water vapour at atmospheric pressure are carried out at 40° C., for a time of at least 8 hours, whereas the drying step is carried out at 40° C., under vacuum, for a time of at least 16 hours.

### Claim 19 (depends on 4)

The process according to claim 4, wherein in the purification step d), the pre-drying and the passage in a saturated chamber of water vapour at atmospheric pressure are carried out at 40° C., for a time of at least 8 hours, whereas the drying step is carried out at 40° C., under vacuum, for a time of at least 16 hours.

### Claim 20 (depends on 2)

The process according to claim 2, wherein the starting hyaluronic acid has an average weight molecular weight ranging from 400 to 3×106 Da.

### Claim 21 (depends on 10)

A method of treating cancer, which comprises administering to a patient in need thereof a pharmaceutical composition essentially consisting of the conjugate according to claim 10, associated with pharmacologically acceptable diluents/excipients, wherein the cancer is advanced breast cancer, lung cancer, ovarian cancer, bladder cancer, prostate and endometrial cancer and/or mesothelioma.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the composition is formulated in sterile, isotonic water, containing 5% w/v of glucose.
